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INTRODUCTION 
Type 1 diabetes mellitus (T1DM) is an autoimmune disease 
where the insulin-producing pancreatic β-cells are destroyed 
[1].  Affected individuals would have insulin deficiency, 
leading to the development of hyperglycemia, and unless 
insulin is provided, the patients will succumb to the disease 
[1].  The specific triggers of T1DM is still unknown, but many 
have hypothesized that hygiene and other environmental 
factors contribute to the pathogenesis of T1DM [1]. 
Anti-CD3 (aCD3) is a monoclonal antibody that is known to 
modulate immunity and stop the autoimmune attack on β-cells 
by T-cells [2].  Prolactin (PRL) is a peptide hormone that 
plays an important regulatory role in β-cell adaptation to 
pregnancy [3].  Its known effects include upregulating β-cell 
mass, proliferation, insulin secretion, and downregulating 
apoptosis [3,4].  Glucagon-like peptide 1 (GLP-1) is an 
incretin that is secreted by the L-cells of the distal ileum and 
exhibits effects such as increasing β-cell mass, proliferation, 
insulin secretion and satiety while decreasing glucagon 
secretion and β-cell apoptosis [5,6].  The objectives of this 
research are to determine if the addition of GLP-1 to 
PRL+aCD3 treatment would improve β-cell function in 
diabetic mice and to determine the source of the β-cells in the 
cured mice. 
METHODS 
This experiment was conducted using a non-obese diabetic 
(NOD) mice model.  After the T1DM onset in the NOD mice, 
aCD3 (10 µg/day) was administered to the mice for 5 days, 
PRL (2.7 µg/day) for 21 days, and GLP-1 (10 µg/day) for 21 
days.  Upon reaching the 40th week after initial diabetes onset, 
the mice were sacrificed and the pancreases were taken for 
immunological studies.  β-cell mass, neogenesis, proliferation, 
and apoptosis were determined by performing  
immunohistochemistry (IHC).  Insulin ELISA was used as an 
assay for pancreatic insulin content and secretion. 
RESULTS 
The GLP-1+PRL+aCD3 treatment group had a survival rate of 
83.3% (n=6) resulting in a ~1.8-fold increase over the 
PRL+aCD3 group (n=11) and a ~3.3-fold increase over the 
aCD3 group (n=16). 
 GLP-1 
+PRL+aCD3 
 
PRL+aCD3 
 
aCD3 
 
β-cell fraction  
0.37 ± 0.10%* 
(n=4) 
0.41 ± 0.11%* 
(n=7) 
0.09 ± 0.03% 
(n=7) 
RFP+ β-cell 
fraction  
91.48 ± 0.36% 
(n=2) 
96.31 ± 1.52% 
(n=4) 
93.51 ± 0.73% 
(n=2) 
BrdU+ β-cell 
fraction 
4.65 ± 1.77%* 
(n=3) 
5.21 ± 3.30%* 
(n=7) 
3.57 ± 2.00% 
(n=4) 
TUNEL+ β-
cell fraction  
0.17 ± 0.09% 
(n=3) 
0.54 ± 0.16% 
(n=2) 
0.78 ± 0.27% 
(n=2) 
Figure 1. β-cell fraction, RFP+, BrdU+, and TUNEL+ β-cell 
fractions in various groups.  “*” : p<0.05 in comparison to the 
aCD3 group.  “n” = number of mice in each group. 
DISCUSSION AND CONCLUSIONS 
The group treated with GLP-1+PRL+aCD3 had comparable β-
cell mass to the PRL+aCD3 group. Evidence for β-cell 
neogenesis was determined by quantifying RFP+ β-cells.  
When RFP is expressed on a β-cell, it indicates that the β-cell 
is pre-existing and is not from neogenesis.  Neogenesis did not 
contribute to the β-cell mass since all three groups shared a 
similar RFP+ fraction at a value that is near 100%.  BrdU was 
incorporated in the mice’s DNA to act as a cell proliferation 
marker.  The BrdU+ β-cell fractions were similar between the 
GLP-1+PRL+aCD3 and PRL+aCD3 groups, suggesting that 
GLP-1 does not stimulate β-cells proliferation, above and 
beyond the effect of PRL.  GLP-1, however, may decreases 
the apoptosis of β-cells, as suggested by the lower TUNEL+ β-
cell fraction in the GLP-1+PRL+aCD3 treatment group when 
compared with the PRL+aCD3 group. 
 
GLP-1 was determined to increase the survival of NOD mice, 
however, its underlying mechanisms is still unknown.  
Determining pancreatic insulin content and GLUT2 expression 
in future experiments would identify such mechanisms.  
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